New evidence in food allergies treatment.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
30
5
2024
Statut:
aheadofprint
Résumé
To acknowledge, the newly available treatments for food allergy described in the latest scientific literature, such as oral immunotherapy (OIT), biologics and the combination of them in managing patients with IgE-mediated food allergies. Recent studies suggest that OIT and biologics, alone or together, can have a role as disease-modifying treatments for food allergies. The FDA has recently approved omalizumab as a treatment for food allergy. Other biologics are currently under evaluation and further studies are needed to assess the efficacy and safety of these therapies. The allergology scenario is rapidly evolving, the recent introduction and approval of new therapeutic strategies such as biotechnological drugs and allergen immunotherapy is changing the therapeutic paradigm: we are witnessing a shift from a strategy based on avoiding the trigger and reversing an allergic reaction already in progress, to one that aims to modify the natural history of the disease by acting on the immunological mechanisms that determine it. This approach is consistent with the modern perspective of a personalized patient-tailored medicine. In this opinion review, we will provide a brief analysis of current and future therapeutic options for IgE-mediated food allergy, focusing on OIT, biologics and their combination.
Identifiants
pubmed: 38814736
doi: 10.1097/ACI.0000000000000999
pii: 00130832-990000000-00129
doi:
Banques de données
ClinicalTrials.gov
['NCT04148352', 'NCT05678959', 'NCT03793608', 'NCT03682770', 'NCT05069831', 'NCT03679676']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Johansson SGO. A revised nomenclature for allergy. Allergy Clin Immunol Int 2002; 014:279–287.
Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the diagnosis of IgE mediated food allergy. Allergy 2023; 78:3057–3076.
Baseggio Conrado A, Ierodiakonou D, Gowland MH, et al. Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018. BMJ 2021; 372:n251.
Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 2007; 120:638–646.
Lee AJ, Thalayasingam M, Lee BW. Food allergy in Asia: how does it compare? Asia Pacific Allergy 2013; 3:3–14.
Obeng BB, Amoah AS, Larbi IA, et al. Food allergy in Ghanaian schoolchildren: data on sensitization and reported food allergy. Int Arch Allergy Immunol 2011; 155:63–73.
Jutel M, Agache I, Zemelka-Wiacek M, et al. Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper. Allergy 2023; 269–273.
Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils,. J Allergy Clin Immunol 2010; 125:S73–S80.
Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol 2016; 16:751–765.
Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008; 9:310–318.
Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management,. J Allergy Clin Immunol 2018; 141:41–58.
Simons FER, Ardusso LRF, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014; 7:9.
Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy 2022; 77:357–377.
Mutarelli A, Giavina-Bianchi B, Arasi S, et al. Biologicals in IgE-mediated food allergy. Curr Opin Allergy Clin Immunol 2023; 23:205–209.
Silva DD, Singh C, Arasi S, et al. Systematic review of monotherapy with biologicals for children and adults with IgE-mediated food allergy. Clin Transl Allergy 2022; 12:e12123.
Incorvaia C, Al-Ahmad M, Ansotegui IJ, et al. Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. Allergy 2021; 76:1041–1052.
Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol 2023; 23:317–328.
Ridolo E, Incorvaia C, Heffler E, et al. The present and future of allergen immunotherapy in personalized medicine. J Pers Med 2022; 12:774.
Rudman Spergel AK, Minnicozzi M, Wheatley LM, Togias A. Is allergen immunotherapy in children disease modifying? A review of the evidence. Curr Allergy Asthma Rep 2018; 18:47.
Lommatzsch M, Brusselle GG, Canonica GW, et al. Disease-modifying antiasthmatic drugs. Lancet 2022; 399:1664–1668.
Bousquet J, Lockey R, Malling H. Allergen immunotherapy: therapeutic vaccines for allergic diseases A WHO position paper. J Allergy Clin Immunol 1998; 102:558–562.
Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy. Allergy 2014; 69:1008–1025.
Dantzer JA, Wood RA. Update on omalizumab in allergen immunotherapy. Curr Opin Allergy Clin Immunol 2021; 21:559–568.
Muraro A, De Silva D, Halken S, et al. Managing food allergy: GA2LEN guideline 2022. World Allergy Organ J 2022; 15:100687.
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018; 73:799–815.
Brozek JL, Firmino RT, Bognanni A, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update – XIV – recommendations on CMA immunotherapy. World Allergy Organ J 2022; 15:100646.
Stiefel G, Anagnostou K, Boyle RJ, et al. BSACI guideline for the diagnosis and management of peanut and tree nut allergy. Clin Exp Allergy 2017; 47:719–739.
Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022; 399:359–371.
Dantzer J, Virkud Y, Cox A, et al. Long-term follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial. J Allergy Clin Immunol 2024; 153:AB240.
Anjum S, Ciaccio C. Transitioning from peanut allergen powder-dnfp to peanuts. J Allergy Clin Immunol 2024; 153:AB120.
Petroni D, Archer A, Wang Mlun, et al. Treatment of single and multiple food allergies with ADP101: results of the Harmony Phase 1/2 Trial. J Allergy Clin Immunol 2024; 153:AB240.
Chua GT, Soller L, Kapur S, et al. Real-world safety and effectiveness analysis of low-dose preschool sesame oral immunotherapy. J Allergy Clin Immunol Glob 2024; 3:100171.
Leef C, Horton C, Porter H, et al. Patient and caregiver satisfaction and quality of life during peanut oral immunotherapy at a Pediatric Academic Food Allergy Center. J Allergy Clin Immunol 2024; 153:AB120.
Jones SM, Sicherer SH, Burks AW, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol 2017; 139:1242–1252e9.
Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021; 51:1006–1018.
Muraro A, Lemanske RF, Castells M, et al. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis- PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 2017; 72:1006–1021.
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372:793–795.
Galli SJ. Toward precision medicine and health: opportunities and challenges in allergic diseases. J Allergy Clin Immunol 2016; 137:1289–1300.
Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016; 137:1347–1358.
Leung DYM, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986–993.
Wood R, Togias A, Sicherer S, et al. Omalizumab for the treatment of multiple food allergy (OUtMATCH). J Allergy Clin Immunol 2024; 153:AB378.
Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2023; 11:1134–1146.
Martinez San Ireneo M, Ibanez MD, Fernandez-Caldas E, Carnes J. In vitro and in vivo cross-reactivity studies of legume allergy in a Mediterranean population. Int Arch Allergy Immunol 2008; 147:222–230.
Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy. JCI Insight 2019; 4:e131347.
Smiljkovic D, Blatt K, Stefanzl G, et al. BTK inhibition is a potent approach to block IgE mediated histamine release in human basophils. Allergy 2017; 72:1666–1676.
Suresh RV, Dunnam C, Vaidya D, et al. A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis. J Clin Invest 2023; 133:e172335.
Duan S, Arlian BM, Nycholat CM, et al. Nanoparticles displaying allergen and Siglec-8 ligands suppress IgE-FcεRI–mediated anaphylaxis and desensitize mast cells to subsequent antigen challenge. J Immunol 2021; 206:2290–2300.
Berin C. Jak out of the box: targeting Bruton's tyrosine kinase, sialic acid-binding immunoglobulin-like lectin-8, and Janus kinase 1 in food allergy. Ann Allergy Asthma Immunol 2023; 131:23–28.
Faguer S, Delabesse E, Paul C, Pasquet M. IL-4Rα inhibition for severe “Eosinophilic Gastroenteritis, Allergy, and Anaphylaxis” syndrome due to a gain-of-function variant in STAT6. J Clin Immunol 2024; 44:29.